

Activity of Afatinib in Heavily Pretreated Patients With *ERBB2* Mutation-Positive Advanced NSCLC: Findings From a Global Named Patient Use Program



Solange Peters, MD, PhD,^{a,*} Alessandra Curioni-Fontecedro, MD,^b Hovav Nechushtan, MD, PhD,^c Jin-Yuan Shih, MD, PhD,^d Wei-Yu Liao, MD, PhD,^e Oliver Gautschi, MD,^f Vito Spataro, MD,^g Mojca Unk, MD,^h James Chih-Hsin Yang, MD, PhD,ⁱ Robert M. Lorence, MD, PhD,^j Philippe Carrière, MD,^k Agnieszka Cseh, MD,^l Gee-Chen Chang, MD^m

^aOncology Department, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland

^bDepartment of Hematology and Oncology, Division of Oncology, University Hospital Zurich, Zurich, Switzerland

^cSharet Institute of Oncology, Hadassah Hebrew University Medical Center, Kiryat Hadassah, Jerusalem, Israel

^dDepartment of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan

^eDepartment of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan

^fMedical Oncology, Cantonal Hospital Lucerne, Lucerne, Switzerland

^gDepartment of Medical Oncology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland

^hDepartment for Medical Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia

ⁱDepartment of Oncology, National Taiwan University Hospital, Taipei, Taiwan

^jOncology Research, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut

^kRisk Management Oncology, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut

^lMedical Department, Boehringer Ingelheim RCV GmbH & Co. KG, Vienna, Austria

^mFaculty of Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan; and the Division of Chest Medicine, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan

Received 3 April 2018; revised 3 July 2018; accepted 31 July 2018

Available online - 7 August 2018

ABSTRACT

Introduction: Approximately 1% to 4% of NSCLC tumors harbor erb-b2 receptor tyrosine kinase 2 (*ERBB2*) mutation; there is no approved targeted treatment for this subgroup.

Methods: Patients with stage IV NSCLC that progressed after clinical benefit on erlotinib/gefitinib and/or had activating *EGFR* or *ERBB2* mutations, had exhausted other treatments,

and were ineligible for afatinib trials were enrolled in a named patient use program, receiving afatinib 30 to 50 mg/d on a compassionate basis within routine clinical practice. Efficacy and safety were retrospectively assessed in the subgroup with *ERBB2* mutation-positive NSCLC.

Results: Twenty-eight heavily pretreated patients in the named patient use program had a documented *ERBB2* mutation by local testing. Median time-to-treatment failure

*Corresponding author.

Disclosure: Dr. Peters has received personal fees from Amgen, Astra Zeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Clovis Oncology, Eli Lilly, F. Hoffmann-La Roche, Janssen, Merck Sharp & Dohme, Merck Serono, Pfizer, Regeneron, and Takeda. Dr. Curioni-Fontecedro has received personal fees from Astra Zeneca, Boehringer Ingelheim, Bristol-Myers Squibb, F. Hoffmann-La Roche, Merck Sharp & Dohme, Pfizer, and Takeda. Dr. Shih has received personal fees from Astra Zeneca, Roche, Boehringer Ingelheim, Pfizer, Novartis, Bristol-Myers Squibb, Merck Sharp & Dohme, AbbVie, Eli Lilly, and Chugai. Dr. Liao has received personal fees from Astra Zeneca, Roche, Boehringer Ingelheim, Eli Lilly, Pfizer, Merck Sharp & Dohme, Oncology, Novartis, and Bristol-Myers Squibb. Dr. Yang has received personal fees from Boehringer Ingelheim, Eli Lilly, Bayer, Roche/Genentech/Chugai, Astellas, Merck Sharp & Dohme, Merck Serono, Pfizer, Novartis, Celgene, Merrimack, Yuhan Pharmaceuticals, Bristol-Myers Squibb, Ono Pharmaceuticals, Daiichi Sankyo, and Astra

Zeneca. Dr Lorence has consulted for Boehringer Ingelheim Pharmaceuticals, Inc. Dr. Carriere is an employee of Boehringer Ingelheim Pharmaceuticals, Inc. Dr. Cseh is an employee of Boehringer Ingelheim RCV GmbH & Co. KG. The remaining authors have nothing to disclose.

Address for correspondence: Solange Peters, MD, PhD, Oncology Department, Centre Hospitalier Universitaire Vaudois (CHUV), Rue du Bugnon 46, CH-1011 Lausanne, Switzerland. E-mail: solange.peters@chuv.ch

© 2018 International Association for the Study of Lung Cancer. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

ISSN: 1556-0864

<https://doi.org/10.1016/j.jtho.2018.07.093>

(TTF; time from treatment initiation to discontinuation for any reason) was 2.9 months; eight patients (29%) had TTF greater than 1 year. Objective response rate was 19% (3 of 16 patients with response data achieved partial response) and disease control rate (DCR) was 69% (11 of 16). Among 12 patients for whom type of *ERBB2* mutation was specified, 10 had a p.A775_G776insYVMA insertion in exon 20, four of whom (40%) remained on afatinib for more than 1 year. This subgroup had median TTF of 9.6 months, objective response rate of 33% (two of six), and disease control rate of 100% (six of six).

Conclusions: This analysis of patients treated in clinical practice provides further evidence of the activity of afatinib in *ERBB2* mutation-positive NSCLC, and suggests that identification of specific subgroups with certain mutations, such as p.A775_G776ins/YVMA insertion in exon 20, could help optimize outcomes with ErbB2-targeted treatment.

© 2018 International Association for the Study of Lung Cancer. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Keywords: Afatinib; NSCLC; *ERBB2* mutation

Introduction

Driven by the identification of specific genomic aberrations that underlie oncogenic molecular abnormalities, targeted therapy has significantly enhanced outcomes for patients with NSCLC carrying activating mutations in the *EGFR* gene, or translocations in the ALK receptor tyrosine kinase (*ALK*) gene or *ROS1*.^{1,2} Recently, the first targeted treatment was approved for NSCLC harboring the BRAF V600E mutation.³ However, several other oncogenic drivers have been identified in NSCLC that do not yet have approved targeted treatments; these include mutations in *KRAS*, *MET* proto-oncogene receptor tyrosine kinase (*MET*), *ret* proto-oncogene (*RET*), phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (*PIK3CA*), and erb-b2 receptor tyrosine kinase 2 (*HER2*) genes.^{1,2}

Erb-b2 receptor tyrosine kinase 2 (ErbB2 [HER2]) is a member of the ErbB family of tyrosine kinases, which also includes EGFR (ErbB1), ErbB3, and ErbB4.⁴ Approximately 1% to 4% of NSCLC tumors harbor mutations in the *ERBB2* gene, and in *EGFR/KRAS/ALK*-negative adenocarcinoma specimens, the frequency of *ERBB2* mutations was found to be 6%.^{5,6} In adenocarcinoma, the occurrence of *ERBB2* mutations appears to be almost mutually exclusive to other oncogenic drivers, and although such mutations were initially thought to occur predominantly in this type of NSCLC, they have more recently been observed in squamous cell carcinoma of the lung.^{5,7,8} *ERBB2* mutations are more commonly found in

women and never-smokers than in men and former- or current-smokers, but their prognostic implication is unknown.⁹ There is increasing evidence that the use of anti-ErbB2 agents (such as afatinib, dacomitinib, neratinib, trastuzumab, and the antibody-drug conjugate trastuzumab emtansine [T-DM1]) may elicit objective responses in *ERBB2* mutation-positive NSCLC.⁹⁻¹⁵ In addition, the pan-ErbB tyrosine kinase inhibitor (TKI) poziotinib is currently being investigated in a phase II clinical trial of patients with advanced NSCLC, including those with insertion mutations in exon 20 of *ERBB2* (clinical trials no. NCT03318939).

Afatinib is a selective inhibitor of the ErbB protein family, which irreversibly blocks signaling of all homodimers and heterodimers formed by these proteins.^{16,17} Having been approved in the United States and European Union in 2013 for the treatment of *EGFR* mutation-positive NSCLC (and subsequently in several other regions), afatinib has more recently been approved for the treatment of metastatic squamous NSCLC that has progressed after platinum-based chemotherapy. Initial results for the treatment of *ERBB2* mutation-positive NSCLC with afatinib have been encouraging, with objective response or disease control observed in two case series.^{7,18} In addition, in a recent independent analysis presented while this manuscript was in preparation, among 27 patients with metastatic *ERBB2* mutation-positive NSCLC treated with afatinib, the objective response rate (ORR) was 15%, with partial responses (PRs) lasting 5 to 10 months.¹⁹ Similarly, of 13 pretreated patients with *ERBB2* mutation-positive NSCLC who were enrolled in the phase II NICHE trial, 1 (8%) achieved a PR and 7 (54%) achieved disease control after 12 weeks of afatinib treatment.²⁰ These findings, although modest and limited by low patient numbers, confirm that afatinib has clinical activity in some patients with *ERBB2* mutation-positive NSCLC.

A large pool of data is available for heavily pretreated patients who received afatinib under a named patient use (NPU) program. The program was initiated after the results of the phase IIb/III LUX-Lung 1 trial were reported; in LUX-Lung 1, afatinib (50 mg/d) improved progression-free survival and ORR versus placebo in patients with advanced NSCLC who had failed previous treatment with the EGFR TKIs erlotinib or gefitinib and at least one line of chemotherapy.²¹ Under the NPU program, afatinib was made available on a compassionate use basis to patients with no remaining established treatment option who were ineligible for participation in afatinib trials; this included patients with activating *EGFR* or *ERBB2* mutations, with or without a history of failed erlotinib or gefitinib treatment. The afatinib NPU program is therefore a global source of real-world data. Between May 2010 and January 2016, more than 5600 patients with NSCLC received afatinib under the NPU program, and almost 4000 patients were

eligible for inclusion in an analysis of the efficacy and safety of afatinib in this setting; among those for whom response data were available, 23.4% achieved an objective response.²² Here, we report treatment outcomes for the subset of patients with *ERBB2* mutation-positive NSCLC who were treated as part of the NPU program.

Materials and Methods

Patient Enrollment

Patients were eligible to enroll in the afatinib NPU program if they had pathologically confirmed stage IV adenocarcinoma of the lung; had progressed after clinical benefit on erlotinib or gefitinib ("clinical benefit" being defined as stable disease [SD] for at least 6 months, or a complete response [CR] or PR) and/or had an activating mutation in *EGFR* or *ERBB2*; had exhausted all other treatment options (chemotherapy-naïve patients were eligible if they had been deemed unfit for chemotherapy); and were deemed ineligible to participate in an actively recruiting afatinib trial.

The NPU program procedures (including enrollment criteria and treatment details) were adapted locally and approved in each region according to local regulations. Written informed consent was obtained from each patient before participation. Enrollment into the NPU program was stopped in each country once afatinib (GIOTRIF, Boehringer Ingelheim Pharma GmbH & Co., KG, Ingelheim am Rhein, Germany) became available on the market; enrollment had ceased worldwide by January 2016.

Afatinib Treatment

The recommended starting dose for afatinib was 50 mg once daily, as in the LUX-Lung 1 trial.²¹ Lower starting doses of 40 mg or 30 mg once daily were allowed if deemed necessary by the treating physician. Dose modifications were permitted based on tolerability (10-mg steps; maximum dose of 50 mg/d; minimum dose of 30 mg/d). Combination treatment with other anticancer therapies was allowed if deemed necessary by the treating physician and in accordance with local regulations.

Data Reporting

The purpose of the NPU program was to provide early access to afatinib for patients with no other treatment option, while also generating additional safety information on afatinib. Participating physicians were requested to report all serious adverse events (AEs), AEs leading to afatinib dose reduction or discontinuation, and AEs assessed as causally related to afatinib. Standard serious AE forms and reporting procedures were used to record safety data, and local regulations on safety reporting had to be followed. Additional data, provided as anonymized datasets, included age, sex, *EGFR* and *ERBB2* mutation

status and the nature of the specific mutations, disease stage, prior therapies, and comorbidities. Some datasets relating to patient characteristics and efficacy outcomes were incomplete because they were collected via request forms and, whenever possible, follow-up forms were been completed after discontinuation of afatinib. In some countries, local restrictions did not allow collection of patient data, or precluded or limited the use of such data in a publication.

ERBB2 Mutation-Positive Subgroup Analyses

Among patients for whom genotype information was available, those with an activating *ERBB2* mutation were included in these retrospective analyses. In accordance with the inclusion criteria, these patients were not required to have received prior erlotinib or gefitinib. Outcomes (as of April 2017) were evaluated for patients with any *ERBB2* mutation (the overall group), and according to *ERBB2* mutation type.

Time to treatment failure (TTF) was defined as the time from the start of afatinib treatment to the date afatinib was discontinued for any reason (including switching to another drug, death, or end date of available data, whichever occurred first). TTF was calculated in months by dividing the number of days from start to discontinuation of treatment by 30.417.

The ORR was calculated as the sum of patients with a recorded CR or PR, as a proportion of the total number of patients with available response data (those with CR, PR, SD, progressive disease [PD], or mixed response). Disease control rate (DCR) was calculated as the sum of patients categorized as PR, CR, and SD, as a proportion of all patients with available response data (PR + CR + SD + PD + mixed response). There was no independent radiological verification of responses, SD, or PD, so all such response assessments were made by each individual investigator at their discretion as appropriate for a real-world setting. Also, as in a real-world setting, scan frequency and scan methodology were not mandated but left to the discretion of the investigator.

Results

Patient Characteristics

Of 5650 patients with NSCLC from 49 countries enrolled in the NPU program, 3966 patients from 41 countries were included in the overall analysis.²² A total of 28 patients were documented as having *ERBB2* mutation-positive NSCLC (16 patients with *ERBB2* mutations were identified in the original analysis of the overall NPU program population²²; an additional 12 patients have since been identified and were included in the present analysis). These patients were enrolled in Europe (8 in Switzerland, 2 in Spain, 1 each in Belgium,

Germany, The Netherlands, and Slovenia), Taiwan (11 patients), Israel (2 patients), and Argentina (1 patient). Characteristics of the *ERBB2* mutation-positive patients in the NPU program are summarized in Table 1; the median age was 55 years (range: 39 to 93 years), 16 patients (57%) were female, and all had adenocarcinoma histology.

Treatment history was recorded for all 28 patients. Overall, this was a heavily pretreated population; most patients had received at least one prior systemic therapy (n = 26; 93%), and 16 (57%) had received three or more prior systemic therapies (Table 1). Ten patients (36%) had received first-generation EGFR TKIs (erlotinib and/or gefitinib in any treatment line), with only one having a concurrent EGFR mutation (an exon 19 deletion). Seven patients (25%) had received previous anti-ErbB2 treatment, four with trastuzumab only, and three with both trastuzumab and lapatinib.

Treatment with afatinib was initiated at 50 mg once daily in 11 patients (39%) and 40 mg once daily in 17 patients (61%) (Table 1).

ERBB2 Mutation Type

Information on the specific *ERBB2* mutation type was available for 12 patients; all mutations were in exon 20. Among these 12 patients, the most frequently reported *ERBB2* mutation, occurring in 10 patients (83%), was a p.A775_G776insYVMA insertion in exon 20 (Fig. 1).¹⁹ This insertion occurs at amino acids 776–779 and may alternatively be referred to as 2325/YVMA, Y772-A775dup, p.A771-M774dup, ErbB2 G776-YVMA, and ErbB2^{YVMA}.

The other reported mutation was the M774 duplication, which occurred in two patients (17%) (Fig. 1).

Efficacy

Overall *ERBB2* mutation-positive group. Median TTF in all patients with any *ERBB2* mutation (N = 28) was 2.9 months. Eight patients (29%) remained on afatinib for more than 1 year (Table 2). Tumor response data were available for 16 patients (57%). In those patients, the ORR was 19% (three patients achieved PR) and the DCR was 69% (eight patients with SD plus the three patients with PR) (Table 2).

Efficacy by *ERBB2* mutation type. In the subgroup analysis conducted according to *ERBB2* mutation type, patients with the p.A775_G776insYVMA insertion mutation (n = 10; the most common type of *ERBB2* mutation in this study population) had a median TTF of 9.6 months, and four patients (40%) remained on afatinib for more than 1 year. Tumor response data were available for six patients (60%) with the p.A775_G776insYVMA insertion; in those patients, the ORR was 33% (two patients achieved a PR; see patient cases 1 and 2, below) and the DCR was 100% (four patients with SD plus the two patients with a PR) (Table 2).

Neither of the two patients with other specified *ERBB2* mutations (both duplication mutations of M774) remained on afatinib for more than a year; the median TTF was 1.9 months. Response data were unavailable for both of these patients, meaning that the ORR and DCR could not be calculated (Table 2).

Examples of Patients Who Derived Clinical Benefit From Afatinib

A Taiwanese patient with a p.A775_G776insYVMA insertion in exon 20 who achieved PR on afatinib.

This patient was a 67-year-old male ex-smoker from Taiwan with stage IV lung adenocarcinoma, wild-type for *EGFR* and *ALK*, with a *ERBB2* mutation of p.A775_G776insYVMA insertion in exon 20. He had received first-line chemotherapy with cisplatin/pemetrexed; following failure of first-line chemotherapy, afatinib was then initiated at 40 mg upon entering the NPU program. He achieved a PR due to afatinib monotherapy and remained on afatinib monotherapy for 236 days before disease progression was detected (7.8 months' progression-free survival on afatinib monotherapy). Following progression, he was maintained on afatinib, having experienced clear benefit (PR [Fig. 2]), with the addition of other anticancer agents in an attempt to produce a greater degree of response through combination therapy. He received paclitaxel plus afatinib for 172 days. Paclitaxel was then discontinued and gemcitabine initiated while continuing afatinib; only one dose of gemcitabine was

Table 1. Characteristics of Patients With Confirmed *ERBB2* Mutation-Positive NSCLC in the Afatinib NPU Program (N = 28)

Age, y; median (range)	55 (39-93)
Gender, female/male	16 (57) / 12 (43)
Prior systemic treatment	
No. of lines	
0	2 (7)
1	6 (21)
2	4 (14)
3	8 (29)
4	6 (21)
≥5	2 (7)
Prior first-generation EGFR TKI ^a	10 (36)
Prior anti-ErbB2 treatment	7 (25)
Trastuzumab only	4 (14)
Trastuzumab and lapatinib	3 (11)
Afatinib starting dose	
40 mg	17 (61)
50 mg	11 (39)

Values are n (%) unless otherwise stated.

^aErlotinib/gefitinib in any line.

ErbB2, erb-b2 receptor tyrosine kinase 2; NPU, named patient use; TKI, tyrosine kinase inhibitor.




Figure 1. *ERBB2* mutation types identified in patients participating in the NPU program.

administered due to poor tolerability. The patient subsequently received afatinib monotherapy. He remained on afatinib for a total of 508 days (including all periods of monotherapy and combination therapy), constituting a TTF of 16.7 months. Figure 2 shows computed tomography scans at baseline (Fig. 2A, after failing first-line chemotherapy and before afatinib monotherapy) and after 6 weeks of afatinib monotherapy (Fig. 2B), and shows the PR observed during afatinib monotherapy.

A European patient with a p.A775_G776insYVMA insertion in exon 20 who achieved PR on afatinib.

This patient was a 60-year-old female with stage IV adenocarcinoma of both lungs; *ERBB2* genotyping showed duplication of A771-M774 in exon 20, which was later identified as being synonymous to the p.A775_G776insYVMA insertion in exon 20. Before entering the NPU program, the patient had received four

cycles of chemotherapy with cisplatin plus gemcitabine, followed by five cycles of chemotherapy with pemetrexed plus carboplatin, and then erlotinib for 2 months. Afatinib was initiated at 40 mg, as fourth-line systemic therapy, upon entering the NPU program, and a PR was achieved. The patient remained on afatinib monotherapy for 360 days (TTF 11.8 months). Figure 3 shows positron-emission tomography scans taken before initiation of afatinib and after ~3 months of treatment, confirming the PR and showing the reduced activity of metastases after treatment.

Safety

The most common AEs reported to us were diarrhea/gastrointestinal toxicity and skin disorders, which were reported in 10 and eight patients, respectively. Reported AEs (excluding disease progression, metastases, and death unrelated to afatinib and due to disease progression) are presented in Table 3.

Discussion

Real-world data on the use of afatinib were available from the NPU program for 28 heavily pretreated patients with documented *ERBB2* mutation-positive NSCLC. Median TTF for these patients was 2.9 months, and 29% remained on afatinib treatment for more than 1 year. Of the 16 patients for whom tumor response data were available, 19% had an objective response and 69% achieved disease control. There were no unexpected safety findings.

According to the literature, most *ERBB2* mutations are located in exon 20, which encodes part of the kinase

Table 2. Time to Treatment Failure and Tumor Responses in *ERBB2* Mutation-Positive Patients Receiving Afatinib in the NPU Program

	All <i>ERBB2</i> Mutation-Positive Patients	Patients With p.A775_G776insYVMA in Exon 20	Patients With M774dup in Exon 20
n (%)	28 (100)	10 (36)	2 (7)
TTF			
Median TTF, months	2.9	9.6	1.9
TTF > 1 year	8 (29)	4 (40)	0 (0)
Tumor responses			
Patients with response data available	16 (57)	6 (60)	0 (0)
ORR ^a	3 (19)	2 (33)	ND ^c
DCR ^b	11 (69)	6 (100)	ND ^c
PR	3 (19)	2 (33)	ND ^c
SD	8 (50)	4 (67)	ND ^c

Values are n (%) unless otherwise stated.

^aORR = proportion of patients with CR or PR.

^bDCR = proportion of patients with CR, PR, or SD.

^cND = not determined as no response assessments were available.

CR, complete response; DCR, disease control rate; ND, not determined; *ERBB2*, erb-b2 receptor tyrosine kinase 2; NPU, named patient use; ORR, objective response rate; PR, partial response; SD, stable disease; TTF, time to treatment failure.




Figure 2. Computed tomography scans at baseline (A) and after 6 weeks of afatinib treatment (B) in a Taiwanese patient with a p.A775_G776insYVMA insertion in exon 20 who achieved a PR.

domain; these mutations occur with a frequency of 1% to 4% in NSCLC.^{4,6,23,24} In the current analysis, *ERBB2* mutation type was specified for 12 patients; all mutations were in exon 20, and the p.A775_G776insYVMA insertion was the most common, occurring in 10 patients (83%). Two patients (17%) had another specified mutation, the M774 duplication mutation in exon 20. These findings are consistent with a previous report based on 11 patients with *ERBB2* mutation-positive NSCLC, in which all *ERBB2* mutations were insertions or duplications in exon 20, with YVMA insertions being the most common, occurring in 6 patients (55%).⁴ In the current analysis, patients with a p.A775_G776insYVMA insertion in exon 20 (n = 10) appeared to derive the greatest benefit from afatinib treatment (median TTF 9.6 months, compared with 1.9 months in patients with the M774 duplication mutation), although inferences are limited by the small sample size as well as the absence of data for patients with mutations other than p.A775_G776insYVMA insertion or M774 duplication in exon 20.

The findings of this analysis are consistent with previous observations in patients with *ERBB2* mutation-positive NSCLC who received afatinib within a clinical trial setting. For example, in a recent analysis of data from 27 patients with metastatic *ERBB2* mutation-positive lung cancer who participated in an international, multicenter clinical trial between 2009 and 2016, the ORR was 15% (four PRs), compared with 19% in the current analysis.¹⁹ YVMA insertion in exon 20 was the most common *ERBB2* mutation type in the clinical trial population (59%), and the three patients who achieved the longest lasting PRs (5 to 10 months) had this mutation.¹⁹ In the NICHE trial, a single-arm phase II study of afatinib in pretreated patients with advanced NSCLC harboring *ERBB2* mutations in exon 20 (n = 13), 7 patients (54%) achieved disease control at 12 weeks.²⁰ Although lack of activity in the other 6 patients meant that the pre-specified criteria for proceeding to further clinical testing were not met, descriptive molecular analysis suggested that prolonged disease stabilization




Figure 3. Positron-emission tomography scans taken (A) before initiation of afatinib and (B) after ~3 months of treatment in a European patient with a p.A775_G776insYVMA insertion in exon 20 who achieved a PR.

Table 3. Adverse Events of Any Grade Reported in *ERBB2* Mutation-Positive Patients Receiving Afatinib in the NPU Program (N = 28)

Event	n
Diarrhea/gastrointestinal toxicity	10
Skin disorders ^a	8
Stomatitis/mucositis/mouth ulceration	4
Respiratory disorders ^b	3
Paronychia	2
Nausea/vomiting	2
Depressed consciousness	1
Septic shock	1
Leukocytosis	1
Paralysis	1

Excludes disease progression, metastases, and deaths unrelated to afatinib and due to disease progression.

^aSkin disorders = acne, dermatitis, dermatosis, pruritus, rash, skin toxicity.

^bRespiratory disorders = Adult Respiratory Distress Syndrome, dyspnea, lung infection, respiratory failure, respiratory insufficiency.

NPU, named patient use; *ERBB2*, erb-b2 receptor kinase 2.

occurred in some patients with YVMA insertions. Therefore, despite the challenges of evaluating larger cohorts of patients with rarer *ERBB2* mutations, there is accumulating evidence that the presence of YVMA insertions in exon 20 identifies a subgroup of patients with *ERBB2* mutation-positive NSCLC for whom afatinib may be a treatment option.

Oncogenic activation of ErbB2 may result from protein overexpression, gene copy number gain (due to gene amplification or chromosome 17 polysomy), and gene mutations that lead to molecular alterations in the ErbB2 receptor; limited emerging data suggest that *ERBB2* gene mutations may be more relevant in lung carcinogenesis than *ERBB2* overexpression or amplification.²⁵ Consequently, to optimize outcomes with ErbB2-targeted therapies in NSCLC, it may be necessary to define the treatment population more precisely. The distinction between *ERBB2* mutation and *ERBB2* amplification is fundamental because these appear to be mutually exclusive forms of *ERBB2* alteration that define distinct clinical entities and represent different therapeutic targets.²⁶ For example, in a phase II study of the irreversible pan-ErbB TKI dacomitinib in patients with *ERBB2*-mutant or amplified lung adenocarcinomas, PRs (lasting 3+, 11, and 14 months) were seen in 12% of patients with *ERBB2* exon 20 mutations, but not in patients with *ERBB2* amplifications.¹³ Further research is required to better understand the biology of the exon 20 YVMA mutation, as well as that of rare *ERBB2* mutations, and to further explore ErbB2-related biomarkers that may help to define patient groups and optimize identification of patients most likely to respond to different forms of ErbB2-targeted therapy.

The importance of precisely defining oncogenic driver *ERBB2* alterations (overexpression or amplification, as

well as nonsynonymous *ERBB2* mutations) is further illustrated by the limited efficacy of established anti-ErbB2 therapies in NSCLC, despite their proven efficacy in *ERBB2*-positive breast cancer. For example, studies of trastuzumab in *ERBB2*-positive NSCLC have yielded disappointing results.²⁷⁻²⁹ Potential benefit was only observed in a small subgroup of patients whose tumors expressed high levels of ErbB2 (immunohistochemistry level 3+) or who had *ERBB2* amplification detected by fluorescence in situ hybridization.^{27,28} By contrast, in a case study of a patient with an *EGFR* exon 21 mutation and a *ERBB2* exon 20 mutation, treatment with trastuzumab and paclitaxel elicited a PR.¹¹ In a recent phase II study of T-DM1 in ErbB2-overexpressing NSCLC, objective response was only seen in immunohistochemistry level 3+ patients (ORR 20%).³⁰ In other phase II studies, T-DM1 was active in patients with *ERBB2* mutation-positive NSCLC with an ORR of 44% (8 of 18 patients) in one study and an ORR of 14% (one of seven patients) in another study.^{14,31}

The safety profile of afatinib has been well established, with diarrhea, rash, and stomatitis being among the most common side effects.^{21,32} Cardiotoxicity is a potential safety concern for all agents targeting ErbB2 because ErbB2 is expressed in the heart and is thought to play a role in normal cardiac function.³³ Heart failure and increased risk of cardiac dysfunction have been reported as AEs in patients treated with trastuzumab.^{34,35} However, there is no evidence of cardiac dysfunction from afatinib clinical trials to date, and there were no heart failure AEs reported in patients with *ERBB2* mutation-positive NSCLC treated with afatinib in this NPU program.³⁶

The NPU program provides a large pool of patients who have received afatinib in “real life” conditions in clinical practice. However, missing information is an inherent limitation in this type of analysis. It is likely that the analysis did not include all patients harboring *ERBB2* mutations, given that genotyping information was not available for all patients; indeed, the frequency of *ERBB2* mutations (28 of 3966 [0.7%]) was slightly lower than the 1% to 4% range reported previously.^{4,5} Other missing information included *ERBB2* mutation type for 16 patients (57%) identified as having *ERBB2* mutation-positive NSCLC, tumor response data for 12 patients (43%), and details of the number of patients who received other anticancer therapies in combination with afatinib. AEs may have been under-reported in this real-world setting compared to clinical trials. Another limitation was that there was no independent, central radiological confirmation of reported responses or disease progression. Survival data were not available for the *ERBB2* mutation-positive patient group; however, interpretation of survival data would be confounded by

the high number of prior therapies received by many patients, and the large variability in the treatment line in which patients received afatinib.

Despite the limitations of this small, retrospective analysis, these data show that afatinib provides clinical benefit for patients with *ERBB2* mutation-positive NSCLC, in particular those harboring the most common *ERBB2* mutation found in lung adenocarcinomas, the p.A775_G776insYVMA insertion in exon 20. This may suggest that, in addition to those with sensitizing *EGFR* mutations, a broader group of patients could benefit from targeted treatment with afatinib. Prospective evaluation of afatinib in *ERBB2* mutation-positive NSCLC patients is therefore warranted, and one phase II study is currently recruiting participants (clinical trial no. NCT02597946).

Acknowledgements

This work was supported by Boehringer Ingelheim. No grant number is applicable. The authors were fully responsible for all content and editorial decisions, were involved at all stages of manuscript development, and have approved the final version. Data were collected by the investigators and were analyzed jointly with the sponsor. Medical writing assistance, funded by Boehringer Ingelheim, was provided by Katharine Williams, PhD, of GeoMed, an Ashfield company, part of UDG Healthcare plc. The authors thank Dr Flavio Solca for providing expertise on *ERBB* mutation nomenclature.

References

1. Kris MG, Johnson BE, Berry LD, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. *JAMA*. 2014;311:1998-2006.
2. Rothschild SI. Targeted therapies in non-small cell lung cancer-beyond EGFR and ALK. *Cancers (Basel)*. 2015;7:930-949.
3. US Food and Drug Administration. TAFINLAR. Highlights of prescribing information. 2017. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/202806s006lbl.pdf. Accessed March 19, 2018.
4. Shigematsu H, Takahashi T, Nomura M, et al. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. *Cancer Res*. 2005;65:1642-1646.
5. Peters S, Zimmermann S. Targeted therapy in NSCLC driven by HER2 insertions. *Transl Lung Cancer Res*. 2014;3:84-88.
6. Arcila ME, Chaft JE, Nafa K, et al. Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas. *Clin Cancer Res*. 2012;18:4910-4918.
7. Mazières J, Peters S, Lepage B, et al. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. *J Clin Oncol*. 2013;31:1997-2003.
8. Goss GD, Felip E, Cobo M, et al. Association of ERBB mutations with clinical outcomes of afatinib- or erlotinib-treated patients with lung squamous cell carcinoma. *JAMA Oncol*. 2018;4:1189-1197.
9. Mazières J, Barlesi F, Filleron T, et al. Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort. *Ann Oncol*. 2016;27:281-286.
10. Besse B, Soria JC, Yao B, et al. Neratinib (N) with or without temsirolimus (TEM) in patients (pts) with non-small cell lung cancer (NSCLC) carrying HER2 somatic mutations: an international randomized phase II study. *Ann Oncol*. 2014;25:abstract LBA39_PR.
11. Cappuzzo F, Bemis L, Varella-Garcia M. HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer. *N Engl J Med*. 2006;354:2619-2621.
12. Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers. *Nature*. 2018;554:189-194.
13. Kris MG, Camidge DR, Giaccone G, et al. Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors. *Ann Oncol*. 2015;26:1421-1427.
14. Li B, Shen R, Buonocore D, et al. OA 14.05 Phase 2 basket trial of ado-trastuzumab emtansine in patients with HER2 mutant or amplified lung cancers. *J Thorac Oncol*. 2017;12(suppl 2):S1783.
15. Weiler D, Diebold J, Strobel K, et al. Rapid response to trastuzumab emtansine in a patient with HER2-driven lung cancer. *J Thorac Oncol*. 2015;10:e16-e17.
16. Li D, Ambrogio L, Shimamura T, et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. *Oncogene*. 2008;27:4702-4711.
17. Solca F, Dahl G, Zoephel A, et al. Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. *J Pharmacol Exp Ther*. 2012;343:342-350.
18. De Grève J, Teugels E, Geers C, et al. Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu. *Lung Cancer*. 2012;76:123-127.
19. Lai W-CV, Lebas L, Milia J, et al. Afatinib in patients with metastatic HER2-mutant lung cancers: an international multicenter study. *J Clin Oncol*. 2017;35:abstract 9071.
20. Smit EF, Peters S, Dziadziuszko R, et al. A single-arm phase II trial of afatinib in pretreated patients with advanced NSCLC harboring a HER2 mutation: the ETOP NICHE trial. *J Clin Oncol*. 2017;35:abstract 9070.
21. Miller VA, Hirsh V, Cadranet J, et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. *Lancet Oncol*. 2012;13:528-538.
22. Cappuzzo F, Soo R, Hochmair M, et al. Global named patient use program of afatinib in advanced non-small-cell lung carcinoma patients who progressed following prior therapies. *Future Oncol*. 2018 [Epub ahead of print].
23. Buttitta F, Barassi F, Fresu G, et al. Mutational analysis of the HER2 gene in lung tumors from Caucasian patients:

- mutations are mainly present in adenocarcinomas with bronchioloalveolar features. *Int J Cancer*. 2006;119:2586-2591.
24. Stephens P, Hunter C, Bignell G, et al. Lung cancer: intragenic ERBB2 kinase mutations in tumours. *Nature*. 2004;431:525-526.
 25. Garrido-Castro AC, Felip E. HER2 driven non-small cell lung cancer (NSCLC): potential therapeutic approaches. *Transl Lung Cancer Res*. 2013;2:122-127.
 26. Li BT, Ross DS, Aisner DL, et al. HER2 amplification and HER2 mutation are distinct molecular targets in lung cancers. *J Thorac Oncol*. 2016;11:414-419.
 27. Gatzemeier U, Groth G, Butts C, et al. Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer. *Ann Oncol*. 2004;15:19-27.
 28. Langer CJ, Stephenson P, Thor A, et al. Trastuzumab in the treatment of advanced non-small-cell lung cancer: is there a role? Focus on Eastern Cooperative Oncology Group study 2598. *J Clin Oncol*. 2004;22:1180-1187.
 29. Lara PN Jr, Laptalo L, Longmate J, et al. Trastuzumab plus docetaxel in HER2/neu-positive non-small-cell lung cancer: a California Cancer Consortium screening and phase II trial. *Clin Lung Cancer*. 2004;5:231-236.
 30. Stinchcombe T, Stahel RA, Bubendorf L, et al. Efficacy, safety, and biomarker results of trastuzumab emtansine (T-DM1) in patients (pts) with previously treated HER2-overexpressing locally advanced or metastatic non-small cell lung cancer (mNSCLC). *J Clin Oncol*. 2017;35:abstract 8509.
 31. Hotta K, Aoe K, Kozuki T, et al. A phase II study of trastuzumab emtansine in HER2-positive non-small cell lung cancer. *J Thorac Oncol*. 2018;13:273-279.
 32. Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. *J Clin Oncol*. 2013;31:3327-3334.
 33. Negro A, Brar BK, Lee KF. Essential roles of Her2/erbB2 in cardiac development and function. *Recent Prog Horm Res*. 2004;59:1-12.
 34. Seidman A, Hudis C, Pierri MK, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. *J Clin Oncol*. 2002;20:1215-1221.
 35. Sengupta PP, Northfelt DW, Gentile F, et al. Trastuzumab-induced cardiotoxicity: heart failure at the crossroads. *Mayo Clinic Proc*. 2008;83:197-203.
 36. Ewer MS, Patel K, O'Brien D, Lorence RM. Cardiac safety of afatinib: a review of data from clinical trials. *Cardio-Oncology*. 2015;1:3.